Feasibility, efficacy and toxicity of carboplatin and paclitaxel as a first-line treatment in elderly patients with ovarian cancer

被引：1
|
作者：
Kotani, N. [1 ]
Katsumata, N. [1 ]
Yonemori, K. [1 ]
Hirakawa, A. [2 ]
Yamamoto, H. [1 ]
Ono, M. [1 ]
Hirata, T. [1 ]
Yunokawa, M. [1 ]
Kouno, T. [1 ]
Shimizu, C. [1 ]
Tamura, K. [1 ]
Fujiwara, Y. [1 ]
机构：
[1] Natl Canc Ctr, Breast & Med Oncol Div, Tokyo, Japan
[2] Tokyo Univ Sci, Grad Sch Engn, Dept Management Sci, Tokyo 162, Japan
来源：
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2009年 / 72卷
关键词：
D O I：
10.1016/S1040-8428(09)70099-X
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S40 / S40
页数：1
相关论文
共 50 条
  • [1] Paclitaxel/carboplatin/gemcitabine as first-line treatment of ovarian cancer
    Hansen, SW
    Geertsen, F
    Stroyer, I
    SEMINARS IN ONCOLOGY, 1999, 26 (01) : 96 - 96
  • [2] Paclitaxel combined with carboplatin in the first-line treatment of advanced ovarian cancer
    Meerpohl, HG
    duBois, A
    Kuhnle, H
    Luck, HJ
    Kreienberg, R
    Mobus, V
    Bauknecht, T
    Kochli, O
    Bochtler, H
    Diergarten, K
    Heuser, A
    SEMINARS IN ONCOLOGY, 1995, 22 (06) : 7 - 12
  • [3] Tolerability of carboplatin, paclitaxel and erlotinib as first-line treatment of ovarian cancer.
    Blank, SV
    Curtin, JP
    Goldman, NA
    Fusco, E
    Lesko, Z
    Hochster, H
    Runowicz, CD
    Wadler, S
    Muggia, FM
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 467S - 467S
  • [4] First-line chemotherapy with epidoxorubicin, paclitaxel, and carboplatin for the treatment of advanced epithelial ovarian cancer patients
    Romanini, A
    Tanganelli, L
    Carnino, F
    Fanucchi, A
    Lionetto, R
    Pastorino, S
    Cosio, S
    Gadducci, A
    Conte, PF
    GYNECOLOGIC ONCOLOGY, 2003, 89 (03) : 354 - 359
  • [5] Patients with carboplatin, paclitaxel, and epirubicin combination as first-line chemotherapy in ovarian cancer
    Kristensen, GB
    Havsten, H
    Kaern, J
    Tropé, C
    SEMINARS IN ONCOLOGY, 1999, 26 (01) : 96 - 96
  • [6] Feasibility of two different first-line carboplatin plus paclitaxel regimens in elderly women with ovarian cancer: A retrospective study
    Delanoy, N.
    Ashton, E.
    Mebarki, S.
    Gisselbrecht, M.
    Nicaise, B.
    Azais, H.
    Koual, M.
    Mongardon, A-S. Bats
    Fournier, L.
    Le Frere-Belda, M-A.
    Medioni, J.
    Paillaud, E.
    Oudard, S.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S796 - S796
  • [7] A multicenter retrospective study to assess feasibility, safety and efficacy of first-line carboplatin-paclitaxel versus carboplatin monotherapy in a frail, elderly epithelial ovarian cancer population
    Merry, Eve
    Kesmez, Ronas Taner
    Yu, Tamara
    Flynn, Michael
    Ledermann, Jonathan
    Lockley, Michelle
    Macdonald, Nicola
    Mccormack, Mary
    Nicum, Shibani
    Crusz, Shanthini
    Miller, Rowan
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024,
  • [8] Toxicity and compliance of first line carboplatin plus paclitaxel in elderly patients with ovarian cancer treated in a single center
    Aziz, M.
    Peschardt, K.
    Herrstedt, J.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2007, 64 : S35 - S35
  • [9] Kinetic modeling and efficacy of intraperitoneal paclitaxel combined with intravenous cyclophosphamide and carboplatin as first-line treatment in ovarian cancer
    Hofstra, LS
    Bos, AME
    de Vries, EGE
    van der Zee, AGJ
    Willemsen, ATM
    Rosing, H
    Beijnen, JH
    Mulder, NH
    Aalders, JG
    Willemse, PHB
    GYNECOLOGIC ONCOLOGY, 2002, 85 (03) : 517 - 523
  • [10] Paclitaxel (Taxol(R)) plus carboplatin as first-line treatment for advanced ovarian cancer
    Ozols, RF
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 1996, 6 : 9 - 12
12345